VeriSIM Life May Newsletter
VeriSIM Life
Introducing BIOiSIM, an AI-driven drug development engine designed to de-risk and inform R&D decision-making.
News and Views from the team at VeriSIM Life
VeriSIM Life’s subject matter experts were busy this month co-leading and speaking at industry events, planning another webinar, and otherwise getting the word out about the groundbreaking potential of BIOiSIM’s AtlasGEN technology. Read on for the details of what we’ve been up to, and reach out to a member of our team to learn how we might help to de-risk your R&D processes.
Reminder: Reserve Your Spot in Upcoming Webinar with Debiopharm
We are excited to host our next webinar with our client Dr. Annick Menetrey from Debiopharm on “Accelerating Clinical Translation of Antibody-Drug Conjugates with Hybrid AI.” Join us on May 30th at 8am PDT/11am EDT to learn about how VeriSIM Life and Debiopharm partnered to scalably investigate first-in-human (FIH) dosing strategies for antibody-drug conjugates to reduce tumor burden safely and effectively.
Topics explored will include:
Meet our Team at the BIO International Convention in June
The BIO International Convention will be held in San Diego this year and is described as “the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe.” We are excited that several members of our team will be at the convention for networking purposes, and we’d strongly encourage you to reach out and book some time to connect with a team member to learn how BIOiSIM could improve your R&D processes.?
领英推荐
Head of Biosimulations, Divesh Bhatt Presenting at AIT Conference 2024?
In September, our Head of Biosimulations Divesh Bhatt?will be presenting at the Association of Inhalation Toxicologists 2024 Conference. AIT has announced the conference topics as the following:?
New Approach Technologies (NAMs), inhaled biologics/proteins, inhalation gene expression and cell therapeutics/biomarkers, intranasal dosing, aerosol generation in-vivo/in-vitro/novel methods and aerosol sampling, wildfires and smoke inhalation toxicology and more.
Dr. Jo Varshney: Winner of the 2024 Great Companies International Women Entrepreneur Award
We are proud to announce that Dr. Jo Varshney has won Great Companies' 2024 International Women Entrepreneur Award! "The past couple of years has taught courage–courage to work through a pandemic, courage to endure financial stress, and courage to take on hard problems. Many are not alone in this! ... Lean into that courage with customers," Dr. Varshney offers as one piece of advice in the award writeup.
Dr. Jo Varshney in Outsourcing Pharma - Companies keen to find alternatives to animal testing - read their views
Earlier this month, Charles River Laboratories International, Inc. revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing. Dr. Jo Varshney was selected to weigh in on this topic, which you can read our overall viewpoint on here. If you’re a member, check out the (paywalled) article now.?
What we’re reading - Study Shows AI Accurately Reads Cardio MRIs
This recent research published in Nature is another great example confirming the potential of well-designed AI systems to improve healthcare for humans, in this case by assisting overburdened cardiologists. We were especially interested in findings showing that the AI actually outperformed cardiologists in diagnosing Pulmonary Arterial Hypertension (PAH)--a highly progressive condition which our drug development subsidiary PulmoSIM Therapeutics is working to address.?